MoonLake Immunotherapeutics (NASDAQ:MLTX), a leading biopharmaceutical company specializing in innovative therapies for inflammatory diseases, recently encountered a significant shift in market perception. The company, known for its development of sonelokimab for specific inflammatory conditions, competes fiercely in the immunotherapy space against other biotech firms aiming to introduce effective treatments.
On September 29, 2025, Jefferies adjusted its stance on MoonLake Immunotherapeutics, downgrading the stock from a "Buy" to a "Hold" rating. This decision by Jefferies reflects a more conservative viewpoint, likely influenced by the latest trial outcomes. At the time of this downgrade, MLTX's stock was trading at $6.14, a stark contrast to its previous highs.
The downgrade was closely tied to the week-16 outcomes of MoonLake's Phase 3 VELA-1 and VELA-2 trials, which assessed the efficacy of sonelokimab against the HiSCR75 endpoint—a measure of a 75% reduction in abscess and inflammatory nodule count. Despite the detailed trial design, the market's response was overwhelmingly negative, resulting in a sharp decrease in MLTX's stock value.
The trials, which enrolled 838 patients, compared a 120mg dose of sonelokimab to a placebo. Following week 16, all participants were administered the 120mg dose until week 48, with a final evaluation at week 52. Despite these comprehensive efforts, the stock has seen a significant downturn, plummeting approximately 89.93%, equivalent to a $55.75 decrease.
As of now, MLTX's stock is valued at $6.25, with daily fluctuations ranging between a low of $5.96 and a high of $7.13. Over the past year, the stock hit a peak of $62.75 and a bottom of $5.95. MoonLake's market capitalization stands at roughly $396.57 million, supported by a trading volume of 76.72 million shares, according to TheFly.
